Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Fulton Bank N.A.

Fulton Bank N.A. raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,628 shares of the medical research company’s stock after acquiring an additional 232 shares during the period. Fulton Bank N.A.’s holdings in Charles River Laboratories International were worth $670,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. State Street Corp lifted its holdings in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 1.7% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock valued at $394,359,000 after buying an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the period. Finally, Earnest Partners LLC raised its position in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after acquiring an additional 110,725 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of several research analyst reports. UBS Group boosted their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. TD Cowen upped their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Finally, Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $187.74 on Friday. The stock has a market capitalization of $9.60 billion, a P/E ratio of 23.50, a P/E/G ratio of 5.00 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm’s 50-day moving average is $193.32 and its two-hundred day moving average is $199.71.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the business earned $2.72 earnings per share. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).